Gastric Ulcers - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Gastric Ulcers - Pipeline Review, H2 2018’, provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers

- The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects

- The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Gastric Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

XuanZhu Pharma Co Ltd

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastric Ulcers – Overview

Gastric Ulcers – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastric Ulcers – Overview

Gastric Ulcers – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastric Ulcers – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Ulcers – Companies Involved in Therapeutics Development

Boryung Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Kukje Pharmaceutical Industry Co Ltd

RaQualia Pharma Inc

XuanZhu Pharma Co Ltd

Gastric Ulcers – Drug Profiles

(lafutidine + irsogladine maleate) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1386 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-14012 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-3571 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KJ-14001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMKS-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0123 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tegoprazan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Ulcers – Dormant Projects

Gastric Ulcers – Discontinued Products

Gastric Ulcers – Product Development Milestones

Featured News & Press Releases

Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations

Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy

Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.

Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)

Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court

Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court

Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals

Oct 23, 2001: Prilosec US litigation

May 02, 2001: AstraZeneca Receives Six Months' Market Exclusivity for Prilosec

May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent

Apr 23, 2001: AstraZeneca Files Lawsuit against Apotex Corporation and Torpharm for Patent Infringement

Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada

Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gastric Ulcers, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Gastric Ulcers, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Gastric Ulcers – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018

Gastric Ulcers – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Gastric Ulcers – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018

Gastric Ulcers – Pipeline by RaQualia Pharma Inc, H2 2018

Gastric Ulcers – Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Gastric Ulcers – Dormant Projects, H2 2018

Gastric Ulcers – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Gastric Ulcers, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Gastric Ulcers, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports